A proof-of-concept study on bioorthogonal-based pretargeting and signal amplify radiotheranostic strategy.

ABSTRACT:

Background

Radiotheranostics differs from the vast majority of other cancer therapies in its capacity for simultaneous imaging and therapy, and it is becoming more widely implemented. A balance between diagnostic and treatment requirements is essential for achieving effective radiotheranostics. Herein, we propose a proof-of-concept strategy aiming to address the profound differences in the specific requirements of the diagnosis and treatment of radiotheranostics.

Results

To validate the concept, we designed an s-tetrazine (Tz) conjugated prostate-specific membrane antigen (PSMA) ligand (DOTA-PSMA-Tz) for ⁶⁸Ga or ¹⁷⁷Lu radiolabeling and tumor radiotheranostics, a trans-cyclooctene (TCO) modified Pd@Au nanoplates (Pd@Au-PEG-TCO) for signal amplification,

SUBMITTER: Yang H 

PROVIDER: S-EPMC10926607 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature